Inflammatory myopathy associated with PD-1 inhibitors
To characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy). We studied 19 Japanese patients with PD-1 myopathy (13 men and 6 women, mean age 70 years), who were referred to Keio University. As control groups, we used 68 patients with anti-signal reco...
Saved in:
Published in | Journal of autoimmunity Vol. 100; pp. 105 - 113 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.06.2019
|
Subjects | |
Online Access | Get full text |
ISSN | 0896-8411 1095-9157 1095-9157 |
DOI | 10.1016/j.jaut.2019.03.005 |
Cover
Loading…
Abstract | To characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy).
We studied 19 Japanese patients with PD-1 myopathy (13 men and 6 women, mean age 70 years), who were referred to Keio University. As control groups, we used 68 patients with anti-signal recognition particle antibodies, 51 patients with anti-aminoacyl transfer RNA synthetase antibodies and 460 healthy subjects.
In regard to muscle-disease severity, 10 patients showed a mild form of disease and 9 patients showed a severe form. Non-small cell lung cancer was the most common underlying cancer. PD-1 inhibitor consisted of 11 nivolumab and 8 pembrolizumab. PD-1 myopathy occurred 29 days on average after the first administration of PD-1 inhibitor. The initial manifestation of muscle weakness was ptosis in 10 patients, 15 patients had ptosis, 13 diplopia, 8 facial muscle weakness, 10 bulbar symptoms, 13 limb weakness, 14 neck weakness, 4 cardiac involvement, 6 respiratory involvement and 16 myalgia. Ocular, facial, cardiac and respiratory involvement and myalgia were more frequently observed than controls. Serum creatine kinase was increased to 5247 IU/L on average. Autoantibodies related to inflammatory myopathy were negative, while anti-striational antibodies were found in 13 (68%) patients. HLA-C*12:02 alleles were more frequently detected than healthy controls. Muscle pathology was characterized by multifocal necrotic myofibers with endomysial inflammation and expression of MHC class I. Immunosuppressive therapy with corticosteroids was generally effective for muscle weakness.
Based on our clinical, histological and immunological findings, PD-1 myopathy is a discrete subset of inflammatory myopathy.
•We characterized the inflammatory myopathy associated with PD-1inhibitors.•Ocular, facial, cardiac and respiratory involvement and myalgia were often found.•Anti-striational antibodies were detected in 13 patients (68%).•Pathology showed multifocal necrotic myofibers and expression of MHC class I.•Corticosteroids were effective with the prompt normalization of CK. |
---|---|
AbstractList | To characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy).OBJECTIVETo characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy).We studied 19 Japanese patients with PD-1 myopathy (13 men and 6 women, mean age 70 years), who were referred to Keio University. As control groups, we used 68 patients with anti-signal recognition particle antibodies, 51 patients with anti-aminoacyl transfer RNA synthetase antibodies and 460 healthy subjects.METHODSWe studied 19 Japanese patients with PD-1 myopathy (13 men and 6 women, mean age 70 years), who were referred to Keio University. As control groups, we used 68 patients with anti-signal recognition particle antibodies, 51 patients with anti-aminoacyl transfer RNA synthetase antibodies and 460 healthy subjects.In regard to muscle-disease severity, 10 patients showed a mild form of disease and 9 patients showed a severe form. Non-small cell lung cancer was the most common underlying cancer. PD-1 inhibitor consisted of 11 nivolumab and 8 pembrolizumab. PD-1 myopathy occurred 29 days on average after the first administration of PD-1 inhibitor. The initial manifestation of muscle weakness was ptosis in 10 patients, 15 patients had ptosis, 13 diplopia, 8 facial muscle weakness, 10 bulbar symptoms, 13 limb weakness, 14 neck weakness, 4 cardiac involvement, 6 respiratory involvement and 16 myalgia. Ocular, facial, cardiac and respiratory involvement and myalgia were more frequently observed than controls. Serum creatine kinase was increased to 5247 IU/L on average. Autoantibodies related to inflammatory myopathy were negative, while anti-striational antibodies were found in 13 (68%) patients. HLA-C*12:02 alleles were more frequently detected than healthy controls. Muscle pathology was characterized by multifocal necrotic myofibers with endomysial inflammation and expression of MHC class I. Immunosuppressive therapy with corticosteroids was generally effective for muscle weakness.RESULTSIn regard to muscle-disease severity, 10 patients showed a mild form of disease and 9 patients showed a severe form. Non-small cell lung cancer was the most common underlying cancer. PD-1 inhibitor consisted of 11 nivolumab and 8 pembrolizumab. PD-1 myopathy occurred 29 days on average after the first administration of PD-1 inhibitor. The initial manifestation of muscle weakness was ptosis in 10 patients, 15 patients had ptosis, 13 diplopia, 8 facial muscle weakness, 10 bulbar symptoms, 13 limb weakness, 14 neck weakness, 4 cardiac involvement, 6 respiratory involvement and 16 myalgia. Ocular, facial, cardiac and respiratory involvement and myalgia were more frequently observed than controls. Serum creatine kinase was increased to 5247 IU/L on average. Autoantibodies related to inflammatory myopathy were negative, while anti-striational antibodies were found in 13 (68%) patients. HLA-C*12:02 alleles were more frequently detected than healthy controls. Muscle pathology was characterized by multifocal necrotic myofibers with endomysial inflammation and expression of MHC class I. Immunosuppressive therapy with corticosteroids was generally effective for muscle weakness.Based on our clinical, histological and immunological findings, PD-1 myopathy is a discrete subset of inflammatory myopathy.CONCLUSIONSBased on our clinical, histological and immunological findings, PD-1 myopathy is a discrete subset of inflammatory myopathy. To characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy). We studied 19 Japanese patients with PD-1 myopathy (13 men and 6 women, mean age 70 years), who were referred to Keio University. As control groups, we used 68 patients with anti-signal recognition particle antibodies, 51 patients with anti-aminoacyl transfer RNA synthetase antibodies and 460 healthy subjects. In regard to muscle-disease severity, 10 patients showed a mild form of disease and 9 patients showed a severe form. Non-small cell lung cancer was the most common underlying cancer. PD-1 inhibitor consisted of 11 nivolumab and 8 pembrolizumab. PD-1 myopathy occurred 29 days on average after the first administration of PD-1 inhibitor. The initial manifestation of muscle weakness was ptosis in 10 patients, 15 patients had ptosis, 13 diplopia, 8 facial muscle weakness, 10 bulbar symptoms, 13 limb weakness, 14 neck weakness, 4 cardiac involvement, 6 respiratory involvement and 16 myalgia. Ocular, facial, cardiac and respiratory involvement and myalgia were more frequently observed than controls. Serum creatine kinase was increased to 5247 IU/L on average. Autoantibodies related to inflammatory myopathy were negative, while anti-striational antibodies were found in 13 (68%) patients. HLA-C*12:02 alleles were more frequently detected than healthy controls. Muscle pathology was characterized by multifocal necrotic myofibers with endomysial inflammation and expression of MHC class I. Immunosuppressive therapy with corticosteroids was generally effective for muscle weakness. Based on our clinical, histological and immunological findings, PD-1 myopathy is a discrete subset of inflammatory myopathy. •We characterized the inflammatory myopathy associated with PD-1inhibitors.•Ocular, facial, cardiac and respiratory involvement and myalgia were often found.•Anti-striational antibodies were detected in 13 patients (68%).•Pathology showed multifocal necrotic myofibers and expression of MHC class I.•Corticosteroids were effective with the prompt normalization of CK. To characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy). We studied 19 Japanese patients with PD-1 myopathy (13 men and 6 women, mean age 70 years), who were referred to Keio University. As control groups, we used 68 patients with anti-signal recognition particle antibodies, 51 patients with anti-aminoacyl transfer RNA synthetase antibodies and 460 healthy subjects. In regard to muscle-disease severity, 10 patients showed a mild form of disease and 9 patients showed a severe form. Non-small cell lung cancer was the most common underlying cancer. PD-1 inhibitor consisted of 11 nivolumab and 8 pembrolizumab. PD-1 myopathy occurred 29 days on average after the first administration of PD-1 inhibitor. The initial manifestation of muscle weakness was ptosis in 10 patients, 15 patients had ptosis, 13 diplopia, 8 facial muscle weakness, 10 bulbar symptoms, 13 limb weakness, 14 neck weakness, 4 cardiac involvement, 6 respiratory involvement and 16 myalgia. Ocular, facial, cardiac and respiratory involvement and myalgia were more frequently observed than controls. Serum creatine kinase was increased to 5247 IU/L on average. Autoantibodies related to inflammatory myopathy were negative, while anti-striational antibodies were found in 13 (68%) patients. HLA-C*12:02 alleles were more frequently detected than healthy controls. Muscle pathology was characterized by multifocal necrotic myofibers with endomysial inflammation and expression of MHC class I. Immunosuppressive therapy with corticosteroids was generally effective for muscle weakness. Based on our clinical, histological and immunological findings, PD-1 myopathy is a discrete subset of inflammatory myopathy. |
Author | Hibino, Makoto Onda, Asako Katsuno, Masahisa Nakahara, Jin Matsubara, Shiro Shiina, Takashi Uruha, Akinori Ohnuki, Yuko Nishino, Ichizo Yutani, Sachiko Ohira, Masayuki Suzuki, Shigeaki Noda, Seiya Takao, Masaki Kamada, Sachiko Nakane, Shunya Hanazono, Akira Seki, Morinobu Yaguchi, Hiroshi Noda, Tomoko Isami, Aiko Hiramatsu, Sumie |
Author_xml | – sequence: 1 givenname: Morinobu surname: Seki fullname: Seki, Morinobu organization: Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan – sequence: 2 givenname: Akinori surname: Uruha fullname: Uruha, Akinori organization: Department of Neurology, Tokyo Metropolitan Neurological Hospital, 2-6-1 Musashidai, Fuchu, Tokyo, 183-0042, Japan – sequence: 3 givenname: Yuko surname: Ohnuki fullname: Ohnuki, Yuko organization: Department of Medical Ethics, Tokai University School of Medicine, 143 Shimokasuya, Isehara-shi, Kanagawa, 259-1193, Japan – sequence: 4 givenname: Sachiko surname: Kamada fullname: Kamada, Sachiko organization: Department of Neurology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan – sequence: 5 givenname: Tomoko surname: Noda fullname: Noda, Tomoko organization: Department of Neurology, Ichinomiya Municipal Hospital, 2-2-22 Bunkyo, Ichinomiya-shi, Aichi, 491-8558, Japan – sequence: 6 givenname: Asako surname: Onda fullname: Onda, Asako organization: Department of Neurology, Jikei University Kashiwa Hospital, 163-1 Kashiwashita Kashiwa-shi, Chiba, 277-8567, Japan – sequence: 7 givenname: Masayuki surname: Ohira fullname: Ohira, Masayuki organization: Department of Neurology, Saitama International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama, 350-1298, Japan – sequence: 8 givenname: Aiko surname: Isami fullname: Isami, Aiko organization: Department of Neurology, Nagaoka Red Cross Hospital, 2-297-1, Sensyu, Nagaoka-shi, Niigata, 940-2085, Japan – sequence: 9 givenname: Sumie surname: Hiramatsu fullname: Hiramatsu, Sumie organization: Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-0914, Japan – sequence: 10 givenname: Makoto surname: Hibino fullname: Hibino, Makoto organization: Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, 1-5-1 Tsujido Kandai, Fujisawa-shi, Kanagawa, 251-0041, Japan – sequence: 11 givenname: Shunya surname: Nakane fullname: Nakane, Shunya organization: Department of Molecular Neurology and Therapeutics, Kumamoto University Hospital, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan – sequence: 12 givenname: Seiya surname: Noda fullname: Noda, Seiya organization: Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466–8550, Japan – sequence: 13 givenname: Sachiko surname: Yutani fullname: Yutani, Sachiko organization: Department of Neurology, Tokai University School of Medicine, 143 Shimokasuya, Isehara-shi, Kanagawa, 259-1193, Japan – sequence: 14 givenname: Akira surname: Hanazono fullname: Hanazono, Akira organization: Department of Neurology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan – sequence: 15 givenname: Hiroshi surname: Yaguchi fullname: Yaguchi, Hiroshi organization: Department of Neurology, Jikei University Kashiwa Hospital, 163-1 Kashiwashita Kashiwa-shi, Chiba, 277-8567, Japan – sequence: 16 givenname: Masaki surname: Takao fullname: Takao, Masaki organization: Department of Neurology, Saitama International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama, 350-1298, Japan – sequence: 17 givenname: Takashi surname: Shiina fullname: Shiina, Takashi organization: Department of Molecular Life Science, Basic Medical Science and Molecular Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara-shi, Kanagawa, 259-1193, Japan – sequence: 18 givenname: Masahisa surname: Katsuno fullname: Katsuno, Masahisa organization: Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466–8550, Japan – sequence: 19 givenname: Jin surname: Nakahara fullname: Nakahara, Jin organization: Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan – sequence: 20 givenname: Shiro surname: Matsubara fullname: Matsubara, Shiro organization: Department of Neurology, Tokyo Metropolitan Neurological Hospital, 2-6-1 Musashidai, Fuchu, Tokyo, 183-0042, Japan – sequence: 21 givenname: Ichizo surname: Nishino fullname: Nishino, Ichizo organization: Department of Neuromuscular Research, National Institute of Neuroscience, And Department of Genome Medicine Development, Medical Genome Center, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8502, Japan – sequence: 22 givenname: Shigeaki surname: Suzuki fullname: Suzuki, Shigeaki email: sgsuzuki@z3.keio.jp organization: Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30862448$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkE9P3DAQRy0EguXPF-ihyrGXpDOJk9hVLxUtFAkJDu3Zsp2J1tsk3tpeqnz7ZrVw4QCnubz3k-ads-PJT8TYB4QCAZvPm2Kjd6koAWUBVQFQH7EVgqxziXV7zFYgZJMLjnjGzmPcACDWdX3KzioQTcm5WLH6buoHPY46-TBn4-y3Oq3nTMfordOJuuyfS-vs8XuOmZvWzrgFjJfspNdDpKvne8F-3_z4df0zv3-4vbv-dp9bDm3Ked2aBnogyateNNqYshcGG8LSaAFc9K0kNIJXZkE7S6WkRvKOW2FIW11dsE-H3W3wf3cUkxpdtDQMeiK_i6pEibA83MKCfnxGd2akTm2DG3WY1curCyAOgA0-xkC9si7p5PyUgnaDQlD7qmqj9lXVvqqCSi1VF7V8pb6svyl9PUi0BHpyFFS0jiZLnQtkk-q8e1v_8kq3g5uc1cMfmt-T_wNBn6Ot |
CitedBy_id | crossref_primary_10_2147_EB_S277760 crossref_primary_10_3233_JND_200504 crossref_primary_10_1002_ccr3_9153 crossref_primary_10_1093_braincomms_fcaa181 crossref_primary_10_1212_NXI_0000000000000735 crossref_primary_10_1097_RHU_0000000000001874 crossref_primary_10_2169_internalmedicine_1222_22 crossref_primary_10_2169_internalmedicine_4467_20 crossref_primary_10_2169_naika_108_1793 crossref_primary_10_1007_s10072_022_05920_4 crossref_primary_10_1186_s42466_022_00226_4 crossref_primary_10_1007_s00262_021_03053_9 crossref_primary_10_1007_s10072_021_05561_z crossref_primary_10_1002_mus_26676 crossref_primary_10_5692_clinicalneurol_cn_001876 crossref_primary_10_3389_fonc_2022_1074821 crossref_primary_10_1210_clinem_dgab829 crossref_primary_10_1093_oncolo_oyac033 crossref_primary_10_3389_fcvm_2021_727445 crossref_primary_10_24911_ejmcr_173_1669055719 crossref_primary_10_1002_art_41713 crossref_primary_10_1080_1744666X_2024_2323966 crossref_primary_10_3389_fphar_2022_774170 crossref_primary_10_1212_WNL_0000000000210031 crossref_primary_10_3389_fgene_2023_1206034 crossref_primary_10_3389_fimmu_2023_1163633 crossref_primary_10_17925_USN_2022_18_1_58 crossref_primary_10_1097_WCO_0000000000001188 crossref_primary_10_1097_ICU_0000000000000608 crossref_primary_10_2169_naika_110_1611 crossref_primary_10_1097_WCO_0000000000000855 crossref_primary_10_1097_CAD_0000000000001665 crossref_primary_10_2169_internalmedicine_6834_20 crossref_primary_10_1016_j_nmd_2020_02_013 crossref_primary_10_1038_s41392_022_01136_2 crossref_primary_10_1111_cen3_12643 crossref_primary_10_1007_s40265_021_01507_z crossref_primary_10_1093_rheumatology_keab249 crossref_primary_10_2957_kanzo_65_327 crossref_primary_10_1155_2020_5126717 crossref_primary_10_3389_fimmu_2021_701951 crossref_primary_10_3389_fneur_2022_1004810 crossref_primary_10_1016_j_neurol_2023_03_003 crossref_primary_10_1093_noajnl_vdab107 crossref_primary_10_2169_internalmedicine_1801_23 crossref_primary_10_1111_ncn3_12563 crossref_primary_10_1002_art_41604 crossref_primary_10_1016_j_mcna_2020_09_009 crossref_primary_10_1080_14740338_2024_2363471 crossref_primary_10_3389_fonc_2022_1053370 crossref_primary_10_3389_fimmu_2021_803410 crossref_primary_10_3389_fmed_2021_762247 crossref_primary_10_1002_emp2_12209 crossref_primary_10_1210_clinem_dgad231 crossref_primary_10_1016_j_rdc_2022_02_002 crossref_primary_10_3390_ijms24065643 crossref_primary_10_3390_ijms21093054 crossref_primary_10_1093_rheumatology_keaa832 crossref_primary_10_1007_s11910_024_01336_z crossref_primary_10_1016_j_praneu_2020_01_012 crossref_primary_10_1016_j_praneu_2023_01_011 crossref_primary_10_1111_cen3_12611 crossref_primary_10_1200_OP_20_00625 crossref_primary_10_2169_internalmedicine_0739_22 crossref_primary_10_1136_jitc_2021_002890 crossref_primary_10_5692_clinicalneurol_cn_001604 crossref_primary_10_5692_clinicalneurol_cn_001725 crossref_primary_10_1007_s11926_023_01120_x crossref_primary_10_1038_s41582_024_01001_6 crossref_primary_10_1007_s00011_023_01780_6 crossref_primary_10_1080_1744666X_2023_2154656 crossref_primary_10_1097_CCO_0000000000000681 crossref_primary_10_1111_cen3_12824 crossref_primary_10_1111_jns_12339 crossref_primary_10_1007_s13760_021_01760_9 crossref_primary_10_5692_clinicalneurol_cn_001443 crossref_primary_10_5692_clinicalneurol_cn_001323 crossref_primary_10_2169_naika_111_1926 |
Cites_doi | 10.1016/j.ejca.2016.12.001 10.1212/WNL.0000000000003160 10.1002/j.1460-2075.1992.tb05481.x 10.1093/brain/aww054 10.1016/j.nmd.2017.01.002 10.1093/annonc/mdw126 10.1097/00000421-198212000-00014 10.1016/j.ctrv.2016.02.001 10.1002/acn3.654 10.1002/rcr2.355 10.1001/jamaneurol.2017.0934 10.1200/JCO.2015.66.1389 10.1093/annonc/mdw655 10.1093/annonc/mdx225 10.1016/j.autrev.2017.05.003 10.1016/S1470-2045(16)30571-X 10.1001/archneurol.2009.229 10.1016/j.ejca.2008.10.026 10.1038/nrneurol.2017.144 10.1161/CIRCULATIONAHA.118.035898 10.1111/nan.12380 10.1126/science.aaa8172 10.1001/jamaneurol.2017.1912 10.1016/S0198-8859(01)00298-1 10.1016/j.ejca.2017.05.041 10.1212/WNL.0000000000004359 10.1016/S0140-6736(66)92356-7 10.1111/j.1399-0039.2012.01941.x 10.1016/j.jneuroim.2010.10.023 10.2169/internalmedicine.1956-18 10.1186/s40425-016-0139-8 10.1056/NEJMoa1609214 10.1093/annonc/mdw558 10.1136/jnnp-2016-313166 10.1097/WCO.0000000000000391 10.1212/WNL.0000000000006124 10.1200/JCO.2017.77.6385 10.1001/jamaoncol.2017.2925 10.1016/j.jneuroim.2014.07.006 10.1056/NEJMra1703481 |
ContentType | Journal Article |
Copyright | 2019 Elsevier Ltd Copyright © 2019 Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: 2019 Elsevier Ltd – notice: Copyright © 2019 Elsevier Ltd. All rights reserved. |
DBID | AAYXX CITATION NPM 7X8 |
DOI | 10.1016/j.jaut.2019.03.005 |
DatabaseName | CrossRef PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1095-9157 |
EndPage | 113 |
ExternalDocumentID | 30862448 10_1016_j_jaut_2019_03_005 S0896841119300393 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29J 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AAAJQ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFRF ABJNI ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFGL ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG CJTIS COF CS3 DM4 DU5 EBS EFBJH EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDU HMG HMK HMO HVGLF HZ~ IHE J1W KOM LG5 LUGTX LZ5 M29 M41 MO0 N9A O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SES SEW SIN SPCBC SSH SSI SSZ T5K WUQ XPP Z5R ZGI ZMT ZU3 ~G- AACTN AAIAV ABLVK ABYKQ AFCTW AFKWA AJBFU AJOXV AMFUW EFLBG LCYCR RIG AAYXX AGRNS CITATION NPM 7X8 |
ID | FETCH-LOGICAL-c407t-457b60f0e943f86abb2f8b16e12ba8048f79e1b843b457dce29e694d4c8beaca3 |
IEDL.DBID | .~1 |
ISSN | 0896-8411 1095-9157 |
IngestDate | Mon Jul 21 11:12:46 EDT 2025 Thu Apr 03 07:08:06 EDT 2025 Thu Apr 24 23:06:49 EDT 2025 Tue Jul 01 03:24:09 EDT 2025 Fri Feb 23 02:20:53 EST 2024 Tue Aug 26 18:13:47 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Autoantibodies Human leucocyte antigen Creatine kinase Programmed cell death 1 Inflammatory myopathy |
Language | English |
License | Copyright © 2019 Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c407t-457b60f0e943f86abb2f8b16e12ba8048f79e1b843b457dce29e694d4c8beaca3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 30862448 |
PQID | 2191009570 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2191009570 pubmed_primary_30862448 crossref_citationtrail_10_1016_j_jaut_2019_03_005 crossref_primary_10_1016_j_jaut_2019_03_005 elsevier_sciencedirect_doi_10_1016_j_jaut_2019_03_005 elsevier_clinicalkey_doi_10_1016_j_jaut_2019_03_005 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | June 2019 2019-06-00 20190601 |
PublicationDateYYYYMMDD | 2019-06-01 |
PublicationDate_xml | – month: 06 year: 2019 text: June 2019 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of autoimmunity |
PublicationTitleAlternate | J Autoimmun |
PublicationYear | 2019 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Onda, Miyagawa, Takahashi, Mina, Takagi, Nishino (bib19) 2019 Ohnuki, Suzuki, Shiina, Uruha, Watanabe, Suzuki (bib36) 2016; 87 Allenbach, Benveniste, Goebel, Stenzel (bib33) 2017; 43 Sharma, Allison (bib2) 2015; 348 Haddox, Shenoy, Shah, Kao, Jain, Halfdanarson (bib14) 2017; 28 Suzuki, Uruha, Suzuki, Nishino (bib29) 2017; 16 Ishida, Agata, Shibahara, Honjo (bib1) 1992; 11 Takamatsu, Nakane, Suzuki, Kosaka, Fukushima, Kimura (bib32) 2018; 5 Yshii, Hohlfeld, Liblau (bib12) 2017; 13 Johnson, Balko, Compton, Chalkias, Gorham, Xu (bib27) 2016; 375 Touat, Maisonobe, Knauss, Ben Hadj Salem, Hervier, Aure (bib16) 2018; 91 Watanabe, Uruha, Suzuki, Nakahara, Hamanaka, Takayama (bib20) 2016; 87 Suzuki, Utsugisawa, Yoshikawa, Motomura, Matsubara, Yokoyama (bib38) 2009; 66 Brahmer, Lacchetti, Schneider, Atkins, Brassil, Caterino (bib4) 2018; 36 Shiina, Suzuki, Ozaki, Taira, Kikkawa, Shigenari (bib26) 2012; 80 Postow, Sidlow, Hellmann (bib5) 2018; 378 Wick, Hertenstein, Platten (bib8) 2016; 17 Allenbach, Keraen, Bouvier, Jooste, Champtiaux, Hervier (bib30) 2016; 139 Suzuki, Ishikawa, Konoeda, Seki, Fukushima, Takahashi (bib17) 2017; 89 Cao, Hollenbach, Shi, Shi, Chopek, Fernandez-Vina (bib28) 2001; 62 Weber, Hodi, Wolchok, Topalian, Schadendorf, Larkin (bib34) 2017; 35 Hottinger (bib7) 2016; 29 Anquetil, Salem, Lebrun-Vignes, Johnson, Mammen, Stenzel (bib15) 2018; 138 Eisenhauer, Therasse, Bogaerts, Schwartz, Sargent, Ford (bib23) 2009; 45 van der Geld, Strauss (bib25) 1966; 1 Makarious, Horwood, Coward (bib40) 2017; 82 Vallet, Gaillet, Weiss, Vanhaecke, Saheb, Touitou (bib13) 2016; 27 Kao, Liao, Markovic, Klein, Naddaf, Staff (bib10) 2017; 74 Hibino, Maeda, Horiuchi, Fukuda, Kondo (bib18) 2018; 6 Haanen, Carbonnel, Robert, Kerr, Peters, Larkin (bib3) 2017; 28 Oken, Creech, Tormey, Horton, Davis, McFadden (bib22) 1982; 5 Spain, Diem, Larkin (bib6) 2016; 44 Bilen, Subudhi, Gao, Tannir, Tu, Sharma (bib31) 2016; 4 Suzuki, Utsugisawa, Nagane, Satoh, Kuwana, Suzuki (bib37) 2011; 230 Gonzalez, Puwanant, Lu, Marks, Zivkovic (bib39) 2017; 27 Suzuki, Yonekawa, Kuwana, Hayashi, Okazaki, Kawaguchi (bib24) 2014; 274 Noguchi, Uruha, Suzuki, Hamanaka, Ohnuki, Tsugawa (bib21) 2017; 74 Haratani, Hayashi, Chiba, Kudo, Yonesaka, Kato (bib35) 2018; 4 Cuzzubbo, Javeri, Tissier, Roumi, Barlog, Doridam (bib9) 2017; 73 Spain, Walls, Julve, O'Meara, Schmid, Kalaitzaki (bib11) 2017; 28 Bilen (10.1016/j.jaut.2019.03.005_bib31) 2016; 4 Allenbach (10.1016/j.jaut.2019.03.005_bib33) 2017; 43 van der Geld (10.1016/j.jaut.2019.03.005_bib25) 1966; 1 Kao (10.1016/j.jaut.2019.03.005_bib10) 2017; 74 Haanen (10.1016/j.jaut.2019.03.005_bib3) 2017; 28 Hibino (10.1016/j.jaut.2019.03.005_bib18) 2018; 6 Postow (10.1016/j.jaut.2019.03.005_bib5) 2018; 378 Haddox (10.1016/j.jaut.2019.03.005_bib14) 2017; 28 Eisenhauer (10.1016/j.jaut.2019.03.005_bib23) 2009; 45 Gonzalez (10.1016/j.jaut.2019.03.005_bib39) 2017; 27 Hottinger (10.1016/j.jaut.2019.03.005_bib7) 2016; 29 Suzuki (10.1016/j.jaut.2019.03.005_bib29) 2017; 16 Ohnuki (10.1016/j.jaut.2019.03.005_bib36) 2016; 87 Suzuki (10.1016/j.jaut.2019.03.005_bib17) 2017; 89 Suzuki (10.1016/j.jaut.2019.03.005_bib37) 2011; 230 Suzuki (10.1016/j.jaut.2019.03.005_bib24) 2014; 274 Sharma (10.1016/j.jaut.2019.03.005_bib2) 2015; 348 Anquetil (10.1016/j.jaut.2019.03.005_bib15) 2018; 138 Yshii (10.1016/j.jaut.2019.03.005_bib12) 2017; 13 Touat (10.1016/j.jaut.2019.03.005_bib16) 2018; 91 Noguchi (10.1016/j.jaut.2019.03.005_bib21) 2017; 74 Watanabe (10.1016/j.jaut.2019.03.005_bib20) 2016; 87 Shiina (10.1016/j.jaut.2019.03.005_bib26) 2012; 80 Suzuki (10.1016/j.jaut.2019.03.005_bib38) 2009; 66 Vallet (10.1016/j.jaut.2019.03.005_bib13) 2016; 27 Haratani (10.1016/j.jaut.2019.03.005_bib35) 2018; 4 Brahmer (10.1016/j.jaut.2019.03.005_bib4) 2018; 36 Cuzzubbo (10.1016/j.jaut.2019.03.005_bib9) 2017; 73 Ishida (10.1016/j.jaut.2019.03.005_bib1) 1992; 11 Wick (10.1016/j.jaut.2019.03.005_bib8) 2016; 17 Takamatsu (10.1016/j.jaut.2019.03.005_bib32) 2018; 5 Spain (10.1016/j.jaut.2019.03.005_bib6) 2016; 44 Spain (10.1016/j.jaut.2019.03.005_bib11) 2017; 28 Makarious (10.1016/j.jaut.2019.03.005_bib40) 2017; 82 Weber (10.1016/j.jaut.2019.03.005_bib34) 2017; 35 Cao (10.1016/j.jaut.2019.03.005_bib28) 2001; 62 Oken (10.1016/j.jaut.2019.03.005_bib22) 1982; 5 Johnson (10.1016/j.jaut.2019.03.005_bib27) 2016; 375 Onda (10.1016/j.jaut.2019.03.005_bib19) 2019 Allenbach (10.1016/j.jaut.2019.03.005_bib30) 2016; 139 |
References_xml | – volume: 43 start-page: 62 year: 2017 end-page: 81 ident: bib33 article-title: Integrated classification of inflammatory myopathies publication-title: Neuropathol. Appl. Neurobiol. – volume: 74 start-page: 1216 year: 2017 end-page: 1222 ident: bib10 article-title: Neurological complications associated with anti-programmed death 1 (PD-1) antibodies publication-title: JAMA Neurol – volume: 138 start-page: 743 year: 2018 end-page: 745 ident: bib15 article-title: Immune checkpoint inhibitor-associated myositis publication-title: Circulation – volume: 27 start-page: 266 year: 2017 end-page: 268 ident: bib39 article-title: Myasthenia triggered by immune checkpoint inhibitors: new case and literature review publication-title: Neuromuscul. Disord. – volume: 1 start-page: 57 year: 1966 end-page: 60 ident: bib25 article-title: Myasthenia gravis. Immunological relationship between striated muscle and thymus publication-title: Lancet – volume: 5 start-page: 1421 year: 2018 end-page: 1427 ident: bib32 article-title: Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia publication-title: Ann Clin Transl Neurol – volume: 87 start-page: 1038 year: 2016 end-page: 1044 ident: bib20 article-title: Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy publication-title: J. Neurol. Neurosurg. Psychiatry – volume: 5 start-page: 649 year: 1982 end-page: 655 ident: bib22 article-title: Toxicity and response criteria of the eastern cooperative Oncology group publication-title: Am. J. Clin. Oncol. – volume: 66 start-page: 1334 year: 2009 end-page: 1338 ident: bib38 article-title: Autoimmune targets of heart and skeletal muscles in myasthenia gravis publication-title: Arch. Neurol. – volume: 87 start-page: 1954 year: 2016 end-page: 1955 ident: bib36 article-title: HLA-DRB1 alleles in immune-mediated necrotizing myopathy publication-title: Neurology – volume: 375 start-page: 1749 year: 2016 end-page: 1755 ident: bib27 article-title: Fulminant myocarditis with combination immune checkpoint blockade publication-title: N. Engl. J. Med. – volume: 139 start-page: 2131 year: 2016 end-page: 2135 ident: bib30 article-title: High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody publication-title: Brain – volume: 73 start-page: 1 year: 2017 end-page: 8 ident: bib9 article-title: Neurological adverse events associated with immune checkpoint inhibitors: review of the literature publication-title: Eur. J. Cancer – volume: 11 start-page: 3887 year: 1992 end-page: 3895 ident: bib1 article-title: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death publication-title: EMBO J. – volume: 4 start-page: 374 year: 2018 end-page: 378 ident: bib35 article-title: Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer publication-title: JAMA Oncol – volume: 230 start-page: 148 year: 2011 end-page: 152 ident: bib37 article-title: Clinical and immunological differences between early and late-onset myasthenia gravis in Japan publication-title: J. Neuroimmunol. – volume: 91 start-page: e985 year: 2018 end-page: e994 ident: bib16 article-title: Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer publication-title: Neurology – volume: 274 start-page: 202 year: 2014 end-page: 208 ident: bib24 article-title: Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies publication-title: J. Neuroimmunol. – volume: 62 start-page: 1009 year: 2001 end-page: 1030 ident: bib28 article-title: Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations publication-title: Hum. Immunol. – year: 2019 ident: bib19 article-title: Pembrolizumab-induced ocular myasthenia gravis with anti-titin antibody and necrotizing myopathy publication-title: Intern. Med. – volume: 348 start-page: 56 year: 2015 end-page: 61 ident: bib2 article-title: The future of immune checkpoint therapy publication-title: Science – volume: 89 start-page: 1127 year: 2017 end-page: 1134 ident: bib17 article-title: Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan publication-title: Neurology – volume: 80 start-page: 305 year: 2012 end-page: 316 ident: bib26 article-title: Super high resolution for single molecule-sequence-based typing of classical HLA loci at the 8-digit level using next generation sequencers publication-title: Tissue Antigens – volume: 17 start-page: e529 year: 2016 end-page: e541 ident: bib8 article-title: Neurological sequelae of cancer immunotherapies and targeted therapies publication-title: Lancet Oncol. – volume: 45 start-page: 228 year: 2009 end-page: 247 ident: bib23 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur. J. Cancer – volume: 28 start-page: iv119 year: 2017 end-page: i142 ident: bib3 article-title: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann. Oncol. – volume: 28 start-page: 377 year: 2017 end-page: 385 ident: bib11 article-title: Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature publication-title: Ann. Oncol. – volume: 36 start-page: 1714 year: 2018 end-page: 1768 ident: bib4 article-title: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical Oncology clinical practice guideline publication-title: J. Clin. Oncol. – volume: 74 start-page: 992 year: 2017 end-page: 999 ident: bib21 article-title: Skeletal muscle involvement in antisynthetase syndrome publication-title: JAMA Neurol – volume: 82 start-page: 128 year: 2017 end-page: 136 ident: bib40 article-title: Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors publication-title: Eur. J. Cancer – volume: 29 start-page: 806 year: 2016 end-page: 812 ident: bib7 article-title: Neurologic complications of immune checkpoint inhibitors publication-title: Curr. Opin. Neurol. – volume: 13 start-page: 755 year: 2017 end-page: 763 ident: bib12 article-title: Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives publication-title: Nat. Rev. Neurol. – volume: 6 year: 2018 ident: bib18 article-title: Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer publication-title: Respirology case reports – volume: 35 start-page: 785 year: 2017 end-page: 792 ident: bib34 article-title: Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma publication-title: J. Clin. Oncol. – volume: 378 start-page: 158 year: 2018 end-page: 168 ident: bib5 article-title: Immune-related adverse events associated with immune checkpoint blockade publication-title: N. Engl. J. Med. – volume: 27 start-page: 1352 year: 2016 end-page: 1353 ident: bib13 article-title: Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma publication-title: Ann. Oncol. – volume: 44 start-page: 51 year: 2016 end-page: 60 ident: bib6 article-title: Management of toxicities of immune checkpoint inhibitors publication-title: Cancer Treat Rev. – volume: 16 start-page: 693 year: 2017 end-page: 700 ident: bib29 article-title: Integrated diagnosis Project for inflammatory myopathies: an association between autoantibodies and muscle pathology publication-title: Autoimmun. Rev. – volume: 4 start-page: 36 year: 2016 ident: bib31 article-title: Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody publication-title: J Immunother Cancer – volume: 28 start-page: 673 year: 2017 end-page: 675 ident: bib14 article-title: Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm publication-title: Ann. Oncol. – volume: 73 start-page: 1 year: 2017 ident: 10.1016/j.jaut.2019.03.005_bib9 article-title: Neurological adverse events associated with immune checkpoint inhibitors: review of the literature publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2016.12.001 – volume: 87 start-page: 1954 year: 2016 ident: 10.1016/j.jaut.2019.03.005_bib36 article-title: HLA-DRB1 alleles in immune-mediated necrotizing myopathy publication-title: Neurology doi: 10.1212/WNL.0000000000003160 – volume: 11 start-page: 3887 year: 1992 ident: 10.1016/j.jaut.2019.03.005_bib1 article-title: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death publication-title: EMBO J. doi: 10.1002/j.1460-2075.1992.tb05481.x – volume: 139 start-page: 2131 year: 2016 ident: 10.1016/j.jaut.2019.03.005_bib30 article-title: High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody publication-title: Brain doi: 10.1093/brain/aww054 – volume: 27 start-page: 266 year: 2017 ident: 10.1016/j.jaut.2019.03.005_bib39 article-title: Myasthenia triggered by immune checkpoint inhibitors: new case and literature review publication-title: Neuromuscul. Disord. doi: 10.1016/j.nmd.2017.01.002 – volume: 27 start-page: 1352 year: 2016 ident: 10.1016/j.jaut.2019.03.005_bib13 article-title: Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma publication-title: Ann. Oncol. doi: 10.1093/annonc/mdw126 – volume: 5 start-page: 649 year: 1982 ident: 10.1016/j.jaut.2019.03.005_bib22 article-title: Toxicity and response criteria of the eastern cooperative Oncology group publication-title: Am. J. Clin. Oncol. doi: 10.1097/00000421-198212000-00014 – volume: 44 start-page: 51 year: 2016 ident: 10.1016/j.jaut.2019.03.005_bib6 article-title: Management of toxicities of immune checkpoint inhibitors publication-title: Cancer Treat Rev. doi: 10.1016/j.ctrv.2016.02.001 – volume: 5 start-page: 1421 year: 2018 ident: 10.1016/j.jaut.2019.03.005_bib32 article-title: Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia publication-title: Ann Clin Transl Neurol doi: 10.1002/acn3.654 – volume: 6 year: 2018 ident: 10.1016/j.jaut.2019.03.005_bib18 article-title: Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer publication-title: Respirology case reports doi: 10.1002/rcr2.355 – volume: 74 start-page: 992 year: 2017 ident: 10.1016/j.jaut.2019.03.005_bib21 article-title: Skeletal muscle involvement in antisynthetase syndrome publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2017.0934 – volume: 35 start-page: 785 year: 2017 ident: 10.1016/j.jaut.2019.03.005_bib34 article-title: Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.66.1389 – volume: 28 start-page: 673 year: 2017 ident: 10.1016/j.jaut.2019.03.005_bib14 article-title: Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm publication-title: Ann. Oncol. doi: 10.1093/annonc/mdw655 – volume: 28 start-page: iv119 year: 2017 ident: 10.1016/j.jaut.2019.03.005_bib3 article-title: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx225 – volume: 16 start-page: 693 year: 2017 ident: 10.1016/j.jaut.2019.03.005_bib29 article-title: Integrated diagnosis Project for inflammatory myopathies: an association between autoantibodies and muscle pathology publication-title: Autoimmun. Rev. doi: 10.1016/j.autrev.2017.05.003 – volume: 17 start-page: e529 year: 2016 ident: 10.1016/j.jaut.2019.03.005_bib8 article-title: Neurological sequelae of cancer immunotherapies and targeted therapies publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30571-X – volume: 66 start-page: 1334 year: 2009 ident: 10.1016/j.jaut.2019.03.005_bib38 article-title: Autoimmune targets of heart and skeletal muscles in myasthenia gravis publication-title: Arch. Neurol. doi: 10.1001/archneurol.2009.229 – volume: 45 start-page: 228 year: 2009 ident: 10.1016/j.jaut.2019.03.005_bib23 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 13 start-page: 755 year: 2017 ident: 10.1016/j.jaut.2019.03.005_bib12 article-title: Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives publication-title: Nat. Rev. Neurol. doi: 10.1038/nrneurol.2017.144 – volume: 138 start-page: 743 year: 2018 ident: 10.1016/j.jaut.2019.03.005_bib15 article-title: Immune checkpoint inhibitor-associated myositis publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.118.035898 – volume: 43 start-page: 62 year: 2017 ident: 10.1016/j.jaut.2019.03.005_bib33 article-title: Integrated classification of inflammatory myopathies publication-title: Neuropathol. Appl. Neurobiol. doi: 10.1111/nan.12380 – volume: 348 start-page: 56 year: 2015 ident: 10.1016/j.jaut.2019.03.005_bib2 article-title: The future of immune checkpoint therapy publication-title: Science doi: 10.1126/science.aaa8172 – volume: 74 start-page: 1216 year: 2017 ident: 10.1016/j.jaut.2019.03.005_bib10 article-title: Neurological complications associated with anti-programmed death 1 (PD-1) antibodies publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2017.1912 – volume: 62 start-page: 1009 year: 2001 ident: 10.1016/j.jaut.2019.03.005_bib28 article-title: Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations publication-title: Hum. Immunol. doi: 10.1016/S0198-8859(01)00298-1 – volume: 82 start-page: 128 year: 2017 ident: 10.1016/j.jaut.2019.03.005_bib40 article-title: Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2017.05.041 – volume: 89 start-page: 1127 year: 2017 ident: 10.1016/j.jaut.2019.03.005_bib17 article-title: Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan publication-title: Neurology doi: 10.1212/WNL.0000000000004359 – volume: 1 start-page: 57 year: 1966 ident: 10.1016/j.jaut.2019.03.005_bib25 article-title: Myasthenia gravis. Immunological relationship between striated muscle and thymus publication-title: Lancet doi: 10.1016/S0140-6736(66)92356-7 – volume: 80 start-page: 305 year: 2012 ident: 10.1016/j.jaut.2019.03.005_bib26 article-title: Super high resolution for single molecule-sequence-based typing of classical HLA loci at the 8-digit level using next generation sequencers publication-title: Tissue Antigens doi: 10.1111/j.1399-0039.2012.01941.x – volume: 230 start-page: 148 year: 2011 ident: 10.1016/j.jaut.2019.03.005_bib37 article-title: Clinical and immunological differences between early and late-onset myasthenia gravis in Japan publication-title: J. Neuroimmunol. doi: 10.1016/j.jneuroim.2010.10.023 – year: 2019 ident: 10.1016/j.jaut.2019.03.005_bib19 article-title: Pembrolizumab-induced ocular myasthenia gravis with anti-titin antibody and necrotizing myopathy publication-title: Intern. Med. doi: 10.2169/internalmedicine.1956-18 – volume: 4 start-page: 36 year: 2016 ident: 10.1016/j.jaut.2019.03.005_bib31 article-title: Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody publication-title: J Immunother Cancer doi: 10.1186/s40425-016-0139-8 – volume: 375 start-page: 1749 year: 2016 ident: 10.1016/j.jaut.2019.03.005_bib27 article-title: Fulminant myocarditis with combination immune checkpoint blockade publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1609214 – volume: 28 start-page: 377 year: 2017 ident: 10.1016/j.jaut.2019.03.005_bib11 article-title: Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature publication-title: Ann. Oncol. doi: 10.1093/annonc/mdw558 – volume: 87 start-page: 1038 year: 2016 ident: 10.1016/j.jaut.2019.03.005_bib20 article-title: Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy publication-title: J. Neurol. Neurosurg. Psychiatry doi: 10.1136/jnnp-2016-313166 – volume: 29 start-page: 806 year: 2016 ident: 10.1016/j.jaut.2019.03.005_bib7 article-title: Neurologic complications of immune checkpoint inhibitors publication-title: Curr. Opin. Neurol. doi: 10.1097/WCO.0000000000000391 – volume: 91 start-page: e985 year: 2018 ident: 10.1016/j.jaut.2019.03.005_bib16 article-title: Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer publication-title: Neurology doi: 10.1212/WNL.0000000000006124 – volume: 36 start-page: 1714 year: 2018 ident: 10.1016/j.jaut.2019.03.005_bib4 article-title: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical Oncology clinical practice guideline publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.77.6385 – volume: 4 start-page: 374 year: 2018 ident: 10.1016/j.jaut.2019.03.005_bib35 article-title: Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.2925 – volume: 274 start-page: 202 year: 2014 ident: 10.1016/j.jaut.2019.03.005_bib24 article-title: Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies publication-title: J. Neuroimmunol. doi: 10.1016/j.jneuroim.2014.07.006 – volume: 378 start-page: 158 year: 2018 ident: 10.1016/j.jaut.2019.03.005_bib5 article-title: Immune-related adverse events associated with immune checkpoint blockade publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1703481 |
SSID | ssj0011555 |
Score | 2.5209253 |
Snippet | To characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy).
We studied 19 Japanese patients with PD-1... To characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy).OBJECTIVETo characterize the inflammatory myopathy... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 105 |
SubjectTerms | Autoantibodies Creatine kinase Human leucocyte antigen Inflammatory myopathy Programmed cell death 1 |
Title | Inflammatory myopathy associated with PD-1 inhibitors |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0896841119300393 https://dx.doi.org/10.1016/j.jaut.2019.03.005 https://www.ncbi.nlm.nih.gov/pubmed/30862448 https://www.proquest.com/docview/2191009570 |
Volume | 100 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NS8UwDA-iKF7Eb59fTPAm861r99Gj-MFTUQQVvJV2a3Gie6LPw7v4t5ts3QMPKnjcSFhJml-TJWkA9gsr0yyOZKhZpkPBHJpULOMw1s6WQmPcoql3-Oo6HdyLi4fkYQqOu14YKqv02N9ieoPW_k3fS7P_WlX92yiXaS7QViVvOkypg11ktMsPPydlHujwNJNPiTgkat8409Z4PVGVCB6B_qLT5KfD6SfnszmEzhZhwXuPwVG7wCWYsvUyzLbzJMfLMHflM-UrkJzXDpX90iTRg5fxkEYPjwPttWHLgP7ABjcnIQuq-rEyFY3dWYX7s9O740HoRySEBUZio1AkmUkjF1kpuMtTbUzscsNSy2Kjc7ROl0nLTC64QdKysLG0qRSlKHKDkKv5GkzXw9puQICBUclEoiV3keBIiIEhuiNRqU3hTFL0gHWyUYW_P5zGWDyrrlDsSZE8FclTRVyhPHtwMOF5bW_P-JWadyJXXV8oIplCcP-VK5lwfds5f_LtdVpVaFKUJ9G1HX68KwRxRq5nFvVgvVX3ZPWcQkAMaTf_-dUtmKentthsG6ZHbx92B92akdlt9u0uzBydXw6uvwBWt_SD |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LSsNAcNCKj4v4tj4jeJPQbHbz2GNRS6u2CCp4W3aTXYxoKloP_Xtnk03BgwpekxmyzOy8Mi-A00zzOAkD7kuSSJ8RgyIV8tAPpdE5kxi3SNs7PBzF_Qd29Rg9zsF50wtjyyqd7q91eqWt3ZOOo2bnrSg6d0HK45ShrHJadZjOw4KdThW1YKE7uO6PZskENJlVJSPC-xbB9c7UZV7PtlAEraCbdRr9ZJ9-8j8rO9Rbg1XnQHrd-ozrMKfLDVisV0pON2Bp6JLlmxANSoP8fq3y6N7rdGy3D0896Riic8_-hPVuL3ziFeVToQq7eWcLHnqX9-d9321J8DMMxiY-ixIVBybQnFGTxlKp0KSKxJqESqYooCbhmqiUUYWgeaZDrmPOcpalCrWupNvQKsel3gUPY6OcsEhyagJGERBjQ_RIglyqzKgoawNpaCMyN0LcbrJ4EU2t2LOw9BSWniKgAunZhrMZzls9QONXaNqQXDStoajMBOr3X7GiGda3y_Mn3knDVYFSZVMlstTjzw-BepxY7zMJ2rBTs3t2emqjQIxq9_751WNY7t8Pb8TNYHS9Dyv2TV17dgCtyfunPkQvZ6KO3C3-Ar3y9zQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inflammatory+myopathy+associated+with+PD-1+inhibitors&rft.jtitle=Journal+of+autoimmunity&rft.au=Seki%2C+Morinobu&rft.au=Uruha%2C+Akinori&rft.au=Ohnuki%2C+Yuko&rft.au=Kamada%2C+Sachiko&rft.date=2019-06-01&rft.eissn=1095-9157&rft.volume=100&rft.spage=105&rft_id=info:doi/10.1016%2Fj.jaut.2019.03.005&rft_id=info%3Apmid%2F30862448&rft.externalDocID=30862448 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0896-8411&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0896-8411&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0896-8411&client=summon |